While extensive CVOTs have established that GLP-1 RAs reduce the risk of MACEsin patients with T2D [52], specific data on dual GLP-1/Gcg RAs, such ascotadutide and survodutide, are currently limited. Here, GCG is linked to type 2 diabetes mellitus.